Loading data for REPL — first visit, this takes a few seconds.
Replimune Group, Inc.
12.92 -0.32 (-2.42%)
12.80 -0.93%
- Рыночная капитализация
- $1.22B
- Объём торгов
- 4.09M
- Следующая дата отчётности
- Nov 5, 2026
Replimune Group, Inc. (REPL): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $0 | n/a | n/a |
| EPS | -$0.72 | +$0.05 | +24.21% |
Метрики
- Бид
- 9.76
- Рыночная капитализация
- 1.22B
- Выручка (TTM)
- n/a
- Чистая прибыль (TTM)
- -297M
- 0.94
- -3.15
- n/a
- -6.34
- P/B (TTM)
- 10.27
- P/S (TTM)
- n/a
- Дата отчёта
- Nov 5, 2026
- Аск
- 15.91
- Объём торгов
- 4,085,047
- Ср. объём (20д)
- 4,527,882
- Открытие
- 13.33
- Пред. закрытие
- 13.24
- Диапазон дня
- 12.40 - 13.74
- Диапазон за 52 недели
- 1.50 - 16.33
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании Replimune Group, Inc.
Профиль →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Отрасль Biotechnology
Сектор Healthcare
Дата IPO Jul 20, 2018
Сотрудники 465
Биржа NasdaqGS
Тикер REPL